MODEL VERDICT
Humacyte, Inc. (HUMA)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 6.93 | 2.12 | 1.79 | 21.68 | 9.84 |
| P/B Ratio | 6.93 | 2.12 | 1.79 | 21.68 | 9.84 |
| P/S Ratio | 151.10 | 138.94 | 84.91 | 229.44 | 73.03 |
Insufficient data to determine relative valuation for HUMA.
Fair value could not be computed for HUMA due to insufficient comparable data.
HUMA's current P/E of -1.0x compares to the industry median of 23.5x (45 peers in the group). This represents a -104.1% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
10 analysts cover HUMA with a consensus rating of Buy. The consensus price target is $4.17 (range: $3.00 — $6.00), implying +241.8% upside from the current price. Grade breakdown: Strong Buy (0), Buy (9), Hold (1), Sell (0), Strong Sell (0).
The model confidence score is 43/100, based on: data completeness (0), peer quality (25), historical depth (10), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for HUMA.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.